Elicio Therapeutics Files 8-K
Ticker: ELTX · Form: 8-K · Filed: Jan 23, 2025 · CIK: 1601485
| Field | Detail |
|---|---|
| Company | Elicio Therapeutics, Inc. (ELTX) |
| Form Type | 8-K |
| Filed Date | Jan 23, 2025 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.01 |
| Sentiment | neutral |
Sentiment: neutral
Topics: disclosure, corporate-filing
Related Tickers: ELIO
TL;DR
ELIO filed a standard 8-K, no major news.
AI Summary
Elicio Therapeutics, Inc. filed an 8-K on January 23, 2025, reporting a Regulation FD Disclosure. The company, formerly known as Angion Biomedica Corp. until February 28, 2014, is incorporated in Delaware and headquartered in Boston, Massachusetts. The filing does not contain specific financial figures or material events beyond the standard reporting requirements.
Why It Matters
This filing serves as a standard disclosure for Elicio Therapeutics, Inc., providing public information about its corporate status and regulatory compliance.
Risk Assessment
Risk Level: low — The filing is a routine 8-K disclosure and does not contain information indicating significant new risks.
Key Players & Entities
- Elicio Therapeutics, Inc. (company) — Registrant
- Angion Biomedica Corp. (company) — Former company name
- January 23, 2025 (date) — Date of report
- February 28, 2014 (date) — Date of name change
- 451 D Street, 5th Floor Boston, Massachusetts 02210 (address) — Principal executive offices
FAQ
What is the primary purpose of this 8-K filing?
The primary purpose of this 8-K filing is to provide a Regulation FD Disclosure as of January 23, 2025.
What was Elicio Therapeutics, Inc. formerly known as, and when did the name change occur?
Elicio Therapeutics, Inc. was formerly known as Angion Biomedica Corp., with the name change occurring on February 28, 2014.
Where are Elicio Therapeutics, Inc.'s principal executive offices located?
Elicio Therapeutics, Inc.'s principal executive offices are located at 451 D Street, 5th Floor, Boston, Massachusetts 02210.
In which state was Elicio Therapeutics, Inc. incorporated?
Elicio Therapeutics, Inc. was incorporated in Delaware.
What is the IRS Employer Identification Number for Elicio Therapeutics, Inc.?
The IRS Employer Identification Number for Elicio Therapeutics, Inc. is 11-3430072.
Filing Stats: 512 words · 2 min read · ~2 pages · Grade level 11.7 · Accepted 2025-01-23 16:36:43
Key Financial Figures
- $0.01 — nge on which registered) Common Stock, $0.01 par value per share ELTX The Nasdaq Cap
Filing Documents
- angn-20250123.htm (8-K) — 23KB
- eliciocorporatedeck_0123.htm (EX-99.1) — 42KB
- eliciocorporatedeck_0123001.jpg (GRAPHIC) — 69KB
- eliciocorporatedeck_0123002.jpg (GRAPHIC) — 117KB
- eliciocorporatedeck_0123003.jpg (GRAPHIC) — 219KB
- eliciocorporatedeck_0123004.jpg (GRAPHIC) — 118KB
- eliciocorporatedeck_0123005.jpg (GRAPHIC) — 63KB
- eliciocorporatedeck_0123006.jpg (GRAPHIC) — 104KB
- eliciocorporatedeck_0123007.jpg (GRAPHIC) — 126KB
- eliciocorporatedeck_0123008.jpg (GRAPHIC) — 92KB
- eliciocorporatedeck_0123009.jpg (GRAPHIC) — 96KB
- eliciocorporatedeck_0123010.jpg (GRAPHIC) — 109KB
- eliciocorporatedeck_0123011.jpg (GRAPHIC) — 104KB
- eliciocorporatedeck_0123012.jpg (GRAPHIC) — 47KB
- eliciocorporatedeck_0123013.jpg (GRAPHIC) — 145KB
- eliciocorporatedeck_0123014.jpg (GRAPHIC) — 120KB
- eliciocorporatedeck_0123015.jpg (GRAPHIC) — 101KB
- eliciocorporatedeck_0123016.jpg (GRAPHIC) — 90KB
- eliciocorporatedeck_0123017.jpg (GRAPHIC) — 82KB
- eliciocorporatedeck_0123018.jpg (GRAPHIC) — 114KB
- eliciocorporatedeck_0123019.jpg (GRAPHIC) — 99KB
- eliciocorporatedeck_0123020.jpg (GRAPHIC) — 47KB
- eliciocorporatedeck_0123021.jpg (GRAPHIC) — 121KB
- eliciocorporatedeck_0123022.jpg (GRAPHIC) — 96KB
- eliciocorporatedeck_0123023.jpg (GRAPHIC) — 95KB
- eliciocorporatedeck_0123024.jpg (GRAPHIC) — 96KB
- eliciocorporatedeck_0123025.jpg (GRAPHIC) — 107KB
- eliciocorporatedeck_0123026.jpg (GRAPHIC) — 93KB
- eliciocorporatedeck_0123027.jpg (GRAPHIC) — 86KB
- eliciocorporatedeck_0123028.jpg (GRAPHIC) — 107KB
- eliciocorporatedeck_0123029.jpg (GRAPHIC) — 120KB
- eliciocorporatedeck_0123030.jpg (GRAPHIC) — 85KB
- eliciocorporatedeck_0123031.jpg (GRAPHIC) — 69KB
- 0001601485-25-000009.txt ( ) — 4533KB
- angn-20250123.xsd (EX-101.SCH) — 2KB
- angn-20250123_lab.xml (EX-101.LAB) — 22KB
- angn-20250123_pre.xml (EX-101.PRE) — 13KB
- angn-20250123_htm.xml (XML) — 3KB
01. Regulation FD Disclosure
Item 7.01. Regulation FD Disclosure. On January 23, 2025, Elicio Therapeutics, Inc. (the "Company") uploaded a copy of its corporate presentation to the Company's website, which presentation is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference herein. The exhibit furnished under Item 7.01 of this Current Report on Form 8-K shall not be deemed to be "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall they be deemed incorporated by reference in any filing under the Exchange Act or the Securities Act of 1933, as amended, regardless of any general incorporation language in such filing.
01. Financial Statements and Exhibits
Item 9.01. Financial Statements and Exhibits. (d) Exhibits. Exhibit Number Exhibit Description 99.1 Corporate Presentation dated January 23, 2025. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Elicio Therapeutics, Inc. By: /s/ ROBERT CONNELLY Date: January 23, 2025 Robert Connelly President and Chief Executive Officer (Principal Executive Officer, Principal Financial Officer, and Principal Accounting Officer)